Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M45,992Revenue (TTM) $M19,480Net Margin (%)9.1Altman Z-Score2.1
Enterprise Value $M54,004EPS (TTM) $1.9Operating Margin %12.1Piotroski F-Score6
P/E(ttm)26.1Beneish M-Score-2.8Pre-tax Margin (%)13.7Higher ROA y-yN
Price/Book1.710-y EBITDA Growth Rate %11.1Quick Ratio1.0Cash flow > EarningsY
Price/Sales2.35-y EBITDA Growth Rate %2.5Current Ratio1.3Lower Leverage y-yY
Price/Free Cash Flow9.2y-y EBITDA Growth Rate %0.3ROA % (ttm)3.5Higher Current Ratio y-yY
Dividend Yield %2.7PEG10.4ROE % (ttm)6.6Less Shares Outstanding y-yN
Payout Ratio %71.0Shares Outstanding M914ROIC % (ttm)3.5Gross Margin Increase y-yY

Gurus Latest Trades with TEVA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
TEVAJulian Robertson 2016-03-31 Reduce-2.02%$53.5 - $65.86
($58.8)
$ 50.26-15%Reduce -40.16%356,200
TEVANWQ Managers 2016-03-31 Add0.49%$53.5 - $65.86
($58.8)
$ 50.26-15%Add 42.10%1,961,208
TEVAFirst Eagle Investment 2016-03-31 Reduce-0.4%$53.5 - $65.86
($58.8)
$ 50.26-15%Reduce -56.18%1,915,660
TEVADavid Dreman 2016-03-31 Buy 0.21%$53.5 - $65.86
($58.8)
$ 50.26-15%New holding33,983
TEVAJohn Paulson 2016-03-31 Add0.08%$53.5 - $65.86
($58.8)
$ 50.26-15%Add 0.95%20,602,200
TEVAVanguard Health Care Fund 2016-03-31 Add0.07%$53.5 - $65.86
($58.8)
$ 50.26-15%Add 9.60%6,356,700
TEVABarrow, Hanley, Mewhinney & Strauss 2016-03-31 Reduce-0.03%$53.5 - $65.86
($58.8)
$ 50.26-15%Reduce -2.99%9,315,460
TEVAJohn Keeley 2016-03-31 Add0.02%$53.5 - $65.86
($58.8)
$ 50.26-15%Add 20.34%43,784
TEVARonald Muhlenkamp 2016-03-31 Add$53.5 - $65.86
($58.8)
$ 50.26-15%Add 0.12%177,160
TEVAJulian Robertson 2015-12-31 Buy 5.04%$55.96 - $66.32
($61.94)
$ 50.26-19%New holding595,300
TEVAJohn Paulson 2015-12-31 Add0.97%$55.96 - $66.32
($61.94)
$ 50.26-19%Add 13.39%20,409,300
TEVANWQ Managers 2015-12-31 Reduce-0.89%$55.96 - $66.32
($61.94)
$ 50.26-19%Reduce -42.70%1,380,143
TEVAVanguard Health Care Fund 2015-12-31 Buy 0.76%$55.96 - $66.32
($61.94)
$ 50.26-19%New holding5,800,000
TEVADavid Dreman 2015-12-31 Sold Out -0.24%$55.96 - $66.32
($61.94)
$ 50.26-19%Sold Out0
TEVAFirst Eagle Investment 2015-12-31 Reduce-0.01%$55.96 - $66.32
($61.94)
$ 50.26-19%Reduce -2.14%4,371,619
TEVABarrow, Hanley, Mewhinney & Strauss 2015-12-31 Add0.01%$55.96 - $66.32
($61.94)
$ 50.26-19%Add 0.84%9,602,463
TEVAJohn Keeley 2015-12-31 Add$55.96 - $66.32
($61.94)
$ 50.26-19%Add 1.10%36,385
TEVAJohn Paulson 2015-09-30 Add4.82%$55.08 - $72
($64.84)
$ 50.26-22%Add 786.48%18,000,000
TEVANWQ Managers 2015-09-30 Reduce-0.46%$55.08 - $72
($64.84)
$ 50.26-22%Reduce -19.29%2,408,826
TEVAGeorge Soros 2015-09-30 Sold Out -0.26%$55.08 - $72
($64.84)
$ 50.26-22%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

TEVA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


TEVA: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about TEVA:

    News about TEVA:

    Articles On GuruFocus.com
    Andreas Halvorsen Buys Facebook, Amazon, MasterCard Jun 14 2016 
    Growing Generic Drug Market a Good Opportuity for 2 India Firms May 30 2016 
    Stocks Near 52-Week Lows May 26 2016 
    John Keeley Comments on Teva Pharmaceuticals Apr 26 2016 
    Pfizer-Allergen Merger Deal End Hurts Some Funds But Helps Many Apr 08 2016 
    Time To Buy Allergan Apr 06 2016 
    Health Care Investor Larry Robbins Buys HCA Holdings, Cigna Mar 31 2016 
    Fight Market Malaise with These Four Sector Strategies Mar 30 2016 
    Bernard Horn Comments on Teva Pharmaceutical Mar 21 2016 
    Polaris Global Value Fund Annual Letter 2015 Mar 21 2016 

    More From Other Websites
    Teva Inches Closer to Completion of Allergan Generics Deal Jun 28 2016
    Why Teva Pharma Continues to Sell Assets (TEVA) Jun 28 2016
    What New Medicines Were Recommended during the CHMP’s June Meeting? Jun 28 2016
    Inside the CHMP’s June Meeting and Outcome Jun 28 2016
    Ahead of N.C. expansion, Mayne Pharma makes $652M generics play Jun 28 2016
    [$$] Teva and Allergan Sell Generic Drugs to Impax In Latest Divestiture Jun 28 2016
    Why Are These Five Stocks in the Spotlight? Jun 28 2016
    Teva Pharmaceuticals (TEVA) Stock Climbs on Generic Products Sale Jun 28 2016
    8:00 am Teva Pharma announces FDA acceptance of new drug applications for Fluticasone... Jun 28 2016
    Teva Announces FDA Acceptance of New Drug Applications for Fluticasone Propionate/Salmeterol and... Jun 28 2016
    GAMCO's Top Stock Picks With Howard Ward Jun 28 2016
    Brexit Bargain Buys: 14 More Stocks Picked by Morgan Stanley Jun 28 2016
    Mayne to Buy Generic Drugs From Allergan, Teva for $652 Million Jun 27 2016
    Mayne Pharma nears deal for Teva assets: source Jun 27 2016
    Mayne Pharma nears deal for Teva assets -source Jun 27 2016
    TEVA and Antares Pharma Announce Launch of Generic Imitrex in the United States Jun 27 2016
    Teva and Antares Pharma Announce Launch of Generic Imitrex® in the United States Jun 27 2016
    Short Sellers Increase Bets Against Major Pharmaceutical Stocks Jun 27 2016
    Teva's Cinqaero Gets Positive CHMP View, Decision in 2H16 Jun 27 2016
    Teva Pharma: We're still trying to understand Brexit Jun 26 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)